#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Czech Rheumatology / 2022 - 3

Comorbidities in spondyloarthritits

Czech version

Authors: K. Mintálová
Authors‘ workplace: Revmatologický ústav Praha
Published in: Čes. Revmatol., 30, 2022, No. 3, p. 106-113.
Category: Review Article

Overview

The term spondyloarthritis (SpA) includes inflammatory rheumatic diseases affecting mainly the axial skeleton. Based on the predominant involvement of the axial or peripheral skeleton, we distinguish between peripheral and axial spondyloarthritis. The axial form is characterized by inflammatory back pain developing before the age of 45. In axial spondyloarthritis, we further distinguish between the radiographic form, when sacroiliitis is present on the X-ray image, and the non-radiographic form, when sacroiliitis is captured only on MRI of the sacroiliac joint. Extraspinal manifestations of spondyloarthritis include peripheral articular manifestations, enthesitis, as well as skin, eye, and intestinal involvement (psoriasis, uveitis, inflammatory bowel disease). In addition to these manifestations directly related to SpA, we see some other diseases more often than in the general population (so-called comorbidities). The most important comorbidities in spondyloarthritis include osteoporosis, cardiovascular disease, lung involvement, infections, malignancies, peptic ulcers, and depression. Among the risk factors for cardiovascular diseases, arterial hypertension, smoking, dyslipidemia, and diabetes play an important role. The occurrence of comorbidities is closely Komorbidity u spondyloartritid Adresa pro korespondenci: MUDr. Kateřina Mintálová Revmatologický ústav Na Slupi 4 128 50 Praha 2 e-mail: mintalova@revma.cz Autorka prohlašuje, že není v konfliktu zájmů. Do redakce doručeno: 31. 7. 2022 Čes. Revmatol. 2022; 30(3): 106–113 Mintálová K. Revmatologický ústav Praha 107 related to the activity and duration of the underlying disease, functional disability, and mortality. Screening and care for comorbidities in patients with SpA should be as important as therapy for the underlying disease in optimizing patient care.

Keywords:

ankylosing spondylitis – comorbidities – spondyloarthritis

Sources
  1. Dougados M Spondyloarthritis. Lancet 2011; 377: 2127–2137.
  2. Sizheng Steven Zhao et al. Prevalence and impact of comorbities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology 2020; 59: iv47–iv57.
  3. Nikiphorou E, Ramiro S, va der Heide D, et al. Association of comorbidities in spondyloarthritis with poor function, work disability and quality of life: results from the assessment of Spondyloarthritis International Society Comorbidities in Spondyloarthritis Study. Arthritis Care Res 2018; 70: 1257–1262.
  4. Zhao S, Radner H, Siebert S et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology 2019; 58: 1746–1754.
  5. Gonzáles C, Curbelo R R, Torre Alonso JC, et al. Recommendations for the management of comorbidity in patients with axial spondyloarthritis in clinical practice. Reumato Clinica Engl Ed 2018; 14: 346–359.
  6. Michaud K, Wolfe F. Comorbities in rheumatoid arthritis. Best pract Res Clin Rheumatol 2007; 21(5): 885–906.
  7. Moltó A,Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2016; 75: 1016–1023.
  8. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, van den Bosch, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76(6): 978–991.
  9. El Maghraoui A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C. Osteoporosis, body composition,and bone turnover in ankylosing spondylitis. J Rheumatol 1999; 26: 2205–2209.
  10. Ghozlani I, Ghazi M, Nouijai A, Mounach A, et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 2009; 44: 772–776.
  11. van der Weijden MA, Claushuis TA, Nazari T, et al. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 2012; 31: 1529–1535.
  12. Briot K, Durnez A, Paternotte S, Miceli-Richard C. Bone oedema on MRI is highly associated with low bone mineral density in patients with early inflammatory back pain: results from the DESIR cohort. Ann Rheum Dis 2013; 72: 1914–1919.
  13. Redeker I, Callhoff J, Falk H, et al. The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Res Ther 2020; 22: 210.
  14. Kang J-H, Chen Y-H, Lin H-C. Comorbidity profiles among patients with ankylosing spondylitis: a nation wide population-based study. Ann Rheum Dis 2010; 69(6): 1165–1168.
  15. Vosse D, Heijckmann C, Landewe R, van der Heijde D, van der Linden S. Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatology (Oxford) 2007; 46: 1667–1671.
  16. Briot K, Roux C. Inflammation, bone loss and fracture risk in spondyloarthritis. RMD Open 2015; 1: e000052.
  17. Kang KY, Kim IJ, Jung SM, Kwok SK, Ju JH, Park KS, et al. Incidence and predictors of morphometric vertebral fractures in patients with ankylosing spondylitis. Arthritis Res Ther 2014; 16(3): R124.
  18. Sahuguet J, Fechtenbaum J, Molto A, Etcheto A, Richette P, Dougados M, et al. OP0054 Low incidence of vertebral fractures in early spondyloarthritis: 5-year prospective data of the DESIRE cohort. Ann Rheum Dis 2018; 78(1): 60–65.
  19. Briot K, Etcheto A, Miceli RC, Dougados M, Roux C. Bone lossin patients with earlyinflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort. Rheumatology Oxford 2016; 55: 335–342.
  20. Prieto-Alhambra D, Munoz Ortego J, De Vries F, Vosse D, Arden NK, Bowness P, et al. Ankylosing spondylitis confers substantiallyincreased risk of clinical spine fractures: a nationwide case control study. Osteoporos Int 2015; 26: 85–91.
  21. Briot K, Gossec L, Kolta S, Dougados M, Roux C. Prospective assessment of body weight, body composition and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008; 35: 855–861.
  22. Durnez A. Paternotte S, Fechtenbaum J, Landewé RBM, Dougados M, Roux C, et al. Increase in bone density in patients with spondyloarthritis during anti-tumour necrosis alpha therapy: 6-year followup study. J Rheumatol 2013; 40: 1712–1718.
  23. Prati C, Claudepierre P, Pham T, Wendling D. Mortality in spondylarthritis. Joint Bone Spine 2011; 78: 466–470.
  24. Exarchou S, Lie E, Lindström U, Askling J, Forsblad-d’Elia H, Turesson C, et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis 2016; 75: 1466–1472.
  25. Lai Y, Zhang Y, Mo S, et al. Prevalence of comorbidities and risk factors in spondyloarthritis: results of cross-sectional study. Ann Rheum Dis 2020; 81: e43.
  26. Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta- -analysis. Arthritis Care Res (Hoboken) 2011; 63: 557–563.
  27. Bengtsson K, Forsblad-d’Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population- based cohort study. Arthritis Res Ther 2017; 19(1): 102.
  28. Heslinga SC, Van den Oever IA, van Sijl AM, Peters MJ, van der Horst-Bruinsma IE, Smulders YM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord 2015; 16: 80.
  29. Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current cigarette smoking among adults — United States, 2005–2015. MMWR Morb Mortal Wkly Rep 2016; 65: 1205–1211.
  30. Glintborg B, Højgaard P, Lund Hetland M, Steen Krogh N, Kollerup G, Jensen J, et al. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology (Oxford) 2016; 55: 659–668.
  31. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015; 11: 693–704.
  32. Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45: 283–286.
  33. Peters MJL, van Eijk IC, Smulders YM, Serne E, Dijkmans BAC, van der Horst-Bruinsma IE, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010; 37: 161–166.
  34. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293–298.
  35. Sarmiento-Monroy JC, Amaya-Amaya J, Espinosa-Serna JS, et al. Cardiovascular disease in rheumatoid arthritis: a systematic literature review in Latin America. Arthritis 2012; 2012: 371909.
  36. Kaptoge S, di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132–140.
  37. Paul A, Yeh ET, Chan L. A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol 2005; 16(5): 512–517.
  38. Zwaka TP., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194–1197.
  39. Nurmohamed MT, van der Horst-Bruinsma I, Maksymowych WP. Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Current Rheumatol Rep 2012; 14: 415–421.
  40. Mok CC, Ko GT, Ho LY, et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res 2011; 63: 195–202.
  41. Ramonda R, Lo Nigro A, Modesti V, et al. Atherosclerosis in psoriatic arthritis. Autoimmunity Rev 2011; 10: 773–778.
  42. Husni ME. Comorbidities in psoriatic arthritis. Rheumatic Dis Clinics North America 2015; 41: 677–698.
  43. Rivière E, Etcheto A, den Bosch FV, der Heijde DV, Landewé R, Dougados M, et al. Effect of nsaid consumption on cardiovascular events in spondyloarthritis. Ann Rheum Dis 2017; 76: 336–346.
  44. Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 2015; 163: 409–416.
  45. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47(1): 72–75.
  46. Eters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325–331.
  47. Hallgren R, Berne C. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 1983; 213: 351–355.
  48. Mercer E, Rekedal L, Garg R, et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther 2012; 14(3): R135.
  49. Deyab G, Hokstad I, Whist JE, Smastuen MC, Agewall S, Lyberg T, et al. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. Arthritis Res Ther 2017; 19(1): 232.
  50. van Sijl AM, van Eijk IC, Peters MJL, Serné EH, van der Horst- Bruinsma IE, Smulders YM, et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis 2015; 74: 119–123.
  51. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1): 17–28.
  52. Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 2010; 69: 1756–1761.
  53. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414–422.
  54. Ciang N. Chu-Oi, et al. Risk of tuberculosis in patients with spondyloarthritis: data from a centralized Electronic database in Hong Kong. BMC Musculosceletal Dis 2020; 21: 832.
  55. de Vries MK, Arkema EV, Jonsson J, Bruchfeld J, et al. Tuberculosis risk in ankylosing spondylitis, other spondyloarthritis, and psoriatis arthritis in Sweden: a population based cohort study. Arthritis Care Res 2018; 70: 1563–1567.
  56. Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, et al. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 2014; 66: 1282–1290.
  57. Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006; 65: 1184–1187.
  58. Söderlund S, Granath F, Broström O, Karlén P, Löfberg R, Ekbom A, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010; 138: 1697–1703.
  59. Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26(3): 22–31.
  60. Atzeni F, Carletto A, Foti R, Sebastiani M, Panetta V, Salaffi F, et al. Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. Joint Bone Spine 2018; 85(4): 455–459.
  61. Sizheng Zhao, et al. The prevalence of depression in axial spondloarthritis and its association with disease activity, Arthritis Res Ther 2018; 20(1): 140.
  62. Hroudová J. Iatrogenně navozené deprese. Praktické lékárenství 2018; 14(2): 63–66.
  63. Arévalo M, Lopéz-Medina C, Martinez-Losa M, Moltó A, Font P, et al. Role of HLA-B27 in the comorbidities observed in axial spondyloarthritis: Data from COMOSPA. Joint Bone Spine 2020; 87: 445–448.
  64. Tang M, Lu L, Yu X. Interleukin-17A interweaves the skeletal and immune systems. Front Immunol 2021; 11: 625034.
Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Úvodník
Prof. MUDr. Eduard Cmunt – průkopník české revmatologie
Risk of cardiac and ocular toxicity of synthetic antimalarials in rheumatic diseases
Prevalence of spondyloarthritis in patients with acute anterior uveitis
Interstitial lung disease in systemic connective tissue diseases – risk factors, diagnostic and treatment
Fertility disorder associated with undifferentiated connective tissue disease
Article was published in

Czech Rheumatology

Issue 3
2022 Issue 3
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#